Peptides for Fat Loss: The Complete Research Guide (2026)

Fat-loss and body-weight regulation is one of the most active areas in peptide research. This guide maps the compounds most discussed in that literature — what each one does mechanistically, what published research has examined, and how they compare. It is written strictly for laboratory and educational reference.

The two families of fat-loss peptides

In the research literature, the peptides studied around fat loss fall into two broad groups:

1. Incretin receptor agonists — the GLP-1 class. These are the most studied and the reason the category exploded. They act on gut-hormone receptors that coordinate appetite, insulin response, and energy balance.
2. Metabolic adjuncts — a more experimental set studied for lipolysis, mitochondrial function, or energy expenditure through different mechanisms (not incretin receptors).

Understanding the difference is the key to reading the whole field.

The incretin class: GLP-1, GIP, and glucagon

"Incretins" are intestinal hormones that coordinate the body's response to food. Three receptors matter in this research:

• GLP-1 (glucagon-like peptide-1) — studied for satiety signaling, slowed gastric emptying, and glucose-dependent insulin secretion.
• GIP (glucose-dependent insulinotropic polypeptide) — studied as a potentiator of insulin response and a modulator of adipose tissue.
• Glucagon (GCGR) — studied for its role in energy expenditure and hepatic fat mobilization — a different lever than appetite suppression.

The defining trend of the last few years is adding receptors: from one (GLP-1) to two (GLP-1/GIP) to three (GLP-1/GIP/glucagon). Each added axis is studied for amplifying the metabolic effect. We cover the underlying biology in depth in GLP-1 Agonists: How Incretin Analogs Work.

Semaglutide — the single agonist

Semaglutide is a mono-agonist acting on the GLP-1 receptor. Its pivotal obesity research program (the STEP trials) established the modern benchmark for the class.¹

Tirzepatide — the dual agonist

Tirzepatide activates both GLP-1 and GIP receptors. The SURMOUNT obesity program reported larger average reductions than mono-agonist comparators in its trials.² See Tirzepatide vs Retatrutide for the practical comparison.

Retatrutide — the triple agonist

Retatrutide (development code LY3437943) adds the glucagon receptor on top of GLP-1 and GIP. Its Phase 2 obesity trial, published in the New England Journal of Medicine in 2023, reported some of the largest weight reductions recorded for an injectable incretin agonist, and it is now in the Phase 3 TRIUMPH program.³ Full breakdown in What Is Retatrutide (GLP-3)?.

The metabolic adjuncts

Beyond the incretin class, several compounds are studied for fat metabolism through unrelated pathways. These are generally earlier-stage or preclinical and should be read as research context, not as established interventions:

• MOTS-C — a mitochondrial-derived peptide studied for metabolic regulation, insulin sensitivity, and exercise response.⁴ See What Is MOTS-C?.
• AOD-9604 — a fragment of the growth-hormone molecule (residues 176–191) studied in preclinical models for lipolytic activity without the broader growth-hormone effects.
• Tesamorelin — a stabilized GHRH analog studied for its effect on visceral and hepatic fat via pulsatile endogenous growth-hormone release. See What Is Tesamorelin?.
• 5-Amino-1MQ — a small-molecule NNMT inhibitor studied preclinically for adipocyte metabolism.
• SLU-PP-332 — an ERR (estrogen-related receptor) agonist studied preclinically for exercise-mimetic energy expenditure.

These compounds are studied for different levers — mitochondrial signaling, growth-hormone axis, or energy expenditure — which is why the literature sometimes examines them alongside incretin agonists rather than as replacements.

How the research frames "stacks"

Research programs sometimes study combinations because the compounds act on non-overlapping pathways (for example, an incretin agonist studied alongside a mitochondrial or GHRH-axis compound). In a research setting this is about mechanism coverage, not a protocol. Renova does not provide combination, dosing, or administration guidance — only the compounds and their documentation.

Verification: the part that actually matters

The single most important signal for any research peptide — fat-loss or otherwise — is independent verification. For every compound above, confirm:

• A per-batch Certificate of Analysis from an independent, accredited lab (not in-house).
• HPLC purity (ideally ≥99%) and mass-spectrometry identity confirmation.
• A batch number that matches the COA and the vial you receive.

Every Renova lot is synthesized and lyophilized in the USA, third-party tested in certified U.S. labs, and ships with its own COA. Confirm any lot with Verify Your Vial, and read How to Read a Peptide COA.

Handling and reconstitution

All of these compounds ship as lyophilized (freeze-dried) powder and are reconstituted with bacteriostatic water for laboratory use. To work out concentration (mg/mL) for any vial size, see Understanding Peptide Reconstitution and How to Store Research Peptides.

Explore the metabolic research catalog →

References

1. Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med. 2021;384:989–1002. ↩

2. Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med. 2022;387:205–216. ↩

3. Jastreboff AM, et al. Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. N Engl J Med. 2023;389:514–526. ↩

4. Lee C, et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metab. 2015;21(3):443–454. ↩